{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T05:39:40Z","timestamp":1788932380960,"version":"build-2803163510"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,5,17]]},"DOI":"10.7759\/cureus.15070","type":"journal-article","created":{"date-parts":[[2021,5,17]],"date-time":"2021-05-17T10:06:40Z","timestamp":1621246000000},"source":"Crossref","is-referenced-by-count":20,"title":["The Efficacy of MDMA (3,4-Methylenedioxymethamphetamine) for Post-traumatic Stress Disorder in Humans: A Systematic Review and Meta-Analysis"],"prefix":"10.7759","author":[{"given":"Sarah","family":"Tedesco","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ganeya","family":"Gajaram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahzad","family":"Chida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arham","family":"Ahmad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meghan","family":"Pentak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Kelada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Layth","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepa","family":"Krishnan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oladipo T","family":"Soetan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrance T","family":"Mukona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayodeji","family":"Jolayemi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","unstructured":"What is MDMA?. (2020). Accessed. March 26, 2021: https:\/\/www.drugabuse.gov\/publications\/research-reports\/mdma-ecstasy-abuse\/what-mdma."},{"key":"ref2","unstructured":"Inverse. MDMA steps closer to FDA approval as a drug, but now it needs to leap. (2021). Accessed: March 26, 2021: https:\/\/maps.org\/articles\/6094-inverse-mdma-steps-closer-to-fda-approval-as-a-drug."},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1177\/0269881118806297","article-title":"3,4-Methylenedioxymethamphetamine-assisted psychotherapy for treatment of chronic posttraumatic stress disorder: a randomized phase 2 controlled trial","volume":"32","author":"Ot'alora G M","year":"2018","unstructured":"Ot'alora G M, Grigsby J, Poulter B, et al.. 3,4-Methylenedioxymethamphetamine-assisted psychotherapy for treatment of chronic posttraumatic stress disorder: a randomized phase 2 controlled trial. J Psychopharmacol. 2018, 32:1295-307. 10.1177\/0269881118806297","journal-title":"J Psychopharmacol"},{"key":"ref4","unstructured":"What are the effects of MDMA | National Institutes of Health. (2020). Accessed. March 27, 2021: https:\/\/www.drugabuse.gov\/publications\/research-reports\/mdma-ecstasy-abuse\/what-are-effects-mdma."},{"key":"ref5","unstructured":"PTSD and DSM-5. (2007). Accessed. March 27, 2021: https:\/\/www.ptsd.va.gov\/professional\/treat\/essentials\/dsm5_ptsd.asp."},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2019.109735","article-title":"Efficacy of 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for posttraumatic stress disorder: A systematic review and meta-analysis","volume":"96","author":"Bahji A","year":"2020","unstructured":"Bahji A, Forsyth A, Groll D, Hawken ER. Efficacy of 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for posttraumatic stress disorder: A systematic review and meta-analysis. Prog Neuropsychopharmacol Biol Psychiatry. 2020, 96:109735. 10.1016\/j.pnpbp.2019.109735","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2018.03.003","article-title":"MDMA-assisted psychotherapy for PTSD: are memory reconsolidation and fear extinction underlying mechanisms?","volume":"84","author":"Feduccia AA","year":"2018","unstructured":"Feduccia AA, Mithoefer MC. MDMA-assisted psychotherapy for PTSD: are memory reconsolidation and fear extinction underlying mechanisms?. Prog Neuropsychopharmacol Biol Psychiatry. 2018, 84:221-8. 10.1016\/j.pnpbp.2018.03.003","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/S2215-0366(18)30135-4","article-title":"3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for post-traumatic stress disorder in military veterans, firefighters, and police officers: a randomised, double-blind, dose-response, phase 2 clinical trial","volume":"5","author":"Mithoefer MC","year":"2018","unstructured":"Mithoefer MC, Mithoefer AT, Feduccia AA, et al.. 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for post-traumatic stress disorder in military veterans, firefighters, and police officers: a randomised, double-blind, dose-response, phase 2 clinical trial. Lancet Psychiatry. 2018, 5:486-97. 10.1016\/S2215-0366(18)30135-4","journal-title":"Lancet Psychiatry"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1177\/0269881111405361","article-title":"MDMA intoxication and verbal memory performance: a placebo-controlled pharmaco-MRI study","volume":"25","author":"Kuypers KP","year":"2011","unstructured":"Kuypers KP, Wingen M, Heinecke A, Formisano E, Ramaekers JG. MDMA intoxication and verbal memory performance: a placebo-controlled pharmaco-MRI study. J Psychopharmacol. 2011, 25:1053-61. 10.1177\/0269881111405361","journal-title":"J Psychopharmacol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/S0074-7742(09)88010-0","article-title":"Neural and cardiac toxicities associated with 3,4-methylenedioxymethamphetamine (MDMA)","volume":"88","author":"Baumann MH","year":"2009","unstructured":"Baumann MH, Rothman RB. Neural and cardiac toxicities associated with 3,4-methylenedioxymethamphetamine (MDMA). Int Rev Neurobiol. 2009, 88:257-96. 10.1016\/S0074-7742(09)88010-0","journal-title":"Int Rev Neurobiol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-014-3528-z","article-title":"MDMA effects consistent across laboratories","volume":"231","author":"Kirkpatrick MG","year":"2014","unstructured":"Kirkpatrick MG, Baggott MJ, Mendelson JE, Galloway GP, Liechti ME, Hysek CM, de Wit H. MDMA effects consistent across laboratories. Psychopharmacology (Berl). 2014, 231:3899-905. 10.1007\/s00213-014-3528-z","journal-title":"Psychopharmacology (Berl)"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1080\/13554794.2014.894530","article-title":"Cognitive disorders after sporadic ecstasy use? A case report","volume":"21","author":"Ruis C","year":"2015","unstructured":"Ruis C, Postma A, Bouvy W, van der Ham I. Cognitive disorders after sporadic ecstasy use? A case report. Neurocase. 2015, 21:351-7. 10.1080\/13554794.2014.894530","journal-title":"Neurocase"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1038\/npp.2014.80","article-title":"A window into the intoxicated mind? Speech as an index of psychoactive drug effects","volume":"39","author":"Bedi G","year":"2014","unstructured":"Bedi G, Cecchi GA, Slezak DF, Carrillo F, Sigman M, de Wit H. A window into the intoxicated mind? Speech as an index of psychoactive drug effects. Neuropsychopharmacology. 2014, 39:2340-8. 10.1038\/npp.2014.80","journal-title":"Neuropsychopharmacology"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1007\/BF02105408","article-title":"The development of a clinician-administered PTSD scale","volume":"8","author":"Blake DD","year":"1995","unstructured":"Blake DD, Weathers FW, Nagy LM, Kaloupek DG, Gusman FD, Charney DS, Keane TM. The development of a clinician-administered PTSD scale. J Trauma Stress. 1995, 8:75-90. 10.1007\/BF02105408","journal-title":"J Trauma Stress"},{"key":"ref15","unstructured":"RevMan | Cochrane Training. (2020). Accessed. March 27, 2021: https:\/\/training.cochrane.org\/online-learning\/core-software-cochrane-reviews\/revman."},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne JAC","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, et al.. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019, 366:l4898. 10.1136\/bmj.l4898","journal-title":"BMJ"},{"key":"ref17","article-title":"Chapter 25: Assessing risk of bias in a non-randomized study","author":"Sterne J A","unstructured":"Sterne J A, Hern\u00e1n M A, McAleenan A, Reeves BC, Higgins JPT. Chapter 25: Assessing risk of bias in a non-randomized study. Cochrane Handbook for Systematic Reviews of Interventions. Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (ed): Cochrane Training, Online; https:\/\/training.cochrane.org\/handbook\/current\/chapter-25:"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1080\/02791072.2008.10400637","article-title":"MDMA-assisted psychotherapy using low doses in a small sample of women with chronic posttraumatic stress disorder","volume":"40","author":"Bouso JC","year":"2008","unstructured":"Bouso JC, Doblin R, Farr\u00e9 M, Alc\u00e1zar MA, G\u00f3mez-Jarabo G. MDMA-assisted psychotherapy using low doses in a small sample of women with chronic posttraumatic stress disorder. J Psychoactive Drugs. 2008, 40:225-36. 10.1080\/02791072.2008.10400637","journal-title":"J Psychoactive Drugs"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1177\/0269881110378371","article-title":"The safety and efficacy of 3,4-methylenedioxymethamphetamine- assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: the first randomized controlled pilot study","volume":"25","author":"Mithoefer M","year":"2011","unstructured":"Mithoefer M, Wagner M, Mithoefer A, et al.. The safety and efficacy of 3,4-methylenedioxymethamphetamine- assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: the first randomized controlled pilot study. J Psychopharmacol. 2011, 25:439-452. 10.1177\/0269881110378371","journal-title":"J Psychopharmacol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1177\/0269881112464827","article-title":"A randomized, controlled pilot study of MDMA (\u00b1 3,4-Methylenedioxymethamphetamine)-assisted psychotherapy for treatment of resistant, chronic Post-Traumatic Stress Disorder (PTSD)","volume":"27","author":"Oehen P","year":"2013","unstructured":"Oehen P, Traber R, Widmer V, Schnyder U. A randomized, controlled pilot study of MDMA (\u00b1 3,4-Methylenedioxymethamphetamine)-assisted psychotherapy for treatment of resistant, chronic Post-Traumatic Stress Disorder (PTSD). J Psychopharmacol. 2013, 27:40-52. 10.1177\/0269881112464827","journal-title":"J Psychopharmacol"},{"key":"ref21","article-title":"MDMA-assisted and cognitive-behavioral conjoint therapy (CBCT) in dyads with one member with chronic PTSD","volume":"NCT02876172","author":"Monson C","year":"2019","unstructured":"Monson C, Holland J, Mithoefer M. MDMA-assisted and cognitive-behavioral conjoint therapy (CBCT) in dyads with one member with chronic PTSD. Clinicaltrials.gov. 2019, NCT02876172:","journal-title":"Clinicaltrials.gov"},{"key":"ref22","unstructured":"Open label multi-site study of safety and effects of MDMA-assisted psychotherapy for treatment of PTSD. (2017). Accessed. February 02, 2021.: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03282123."},{"key":"ref23","unstructured":"Study of safety and effects of MDMA-assisted psychotherapy for treatment of PTSD. (2018). Accessed. February 02, 2021: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03485287."},{"key":"ref24","unstructured":"Randomized, double-blind, controlled of MDMA-assisted psychotherapy in 12 subjects with PTSD. (2013). Accessed. February 02, 2021.: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01958593."},{"key":"ref25","unstructured":"Randomized, double-blind, active placebo-controlled pilot study of MDMA-assisted psychotherapy in people with chronic PTSD. (2012). Accessed. February 02, 2021:  https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01689740."},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1177\/0269881112456611","article-title":"Durability of improvement in post-traumatic stress disorder symptoms and absence of harmful effects or drug dependency after 3,4-methylenedioxymethamphetamine-assisted psychotherapy: a prospective long-term follow-up study","volume":"27","author":"Mithoefer MC","year":"2013","unstructured":"Mithoefer MC, Wagner MT, Mithoefer AT, et al.. Durability of improvement in post-traumatic stress disorder symptoms and absence of harmful effects or drug dependency after 3,4-methylenedioxymethamphetamine-assisted psychotherapy: a prospective long-term follow-up study. J Psychopharmacol. 2013, 27:28-39. 10.1177\/0269881112456611","journal-title":"J Psychopharmacol"},{"key":"ref27","article-title":"A Manual for MDMA-Assisted Psychotherapy in the Treatment of Posttraumatic Stress Disorder","author":"Mithoefer M","year":"2016","unstructured":"Mithoefer M. A Manual for MDMA-Assisted Psychotherapy in the Treatment of Posttraumatic Stress Disorder. Multidisciplinary Assiciation for Psychedelic Studies, Santa Cruz; 2016."},{"key":"ref28","unstructured":"MDMA-assisted therapy study protocols. (2021). Accessed. February 3, 2021: https:\/\/maps.org\/research\/mdma."},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-020-05548-2","article-title":"Long-term follow-up outcomes of MDMA-assisted psychotherapy for treatment of PTSD: a longitudinal pooled analysis of six phase 2 trials","volume":"237","author":"Jerome L","year":"2020","unstructured":"Jerome L, Feduccia AA, Wang JB, et al.. Long-term follow-up outcomes of MDMA-assisted psychotherapy for treatment of PTSD: a longitudinal pooled analysis of six phase 2 trials. Psychopharmacology (Berl). 2020, 237:2485-97. 10.1007\/s00213-020-05548-2","journal-title":"Psychopharmacology (Berl)"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-019-05249-5","article-title":"MDMA-assisted psychotherapy for treatment of PTSD: study design and rationale for phase 3 trials based on pooled analysis of six phase 2 randomized controlled trials","volume":"236","author":"Mithoefer MC","year":"2019","unstructured":"Mithoefer MC, Feduccia AA, Jerome L, et al.. MDMA-assisted psychotherapy for treatment of PTSD: study design and rationale for phase 3 trials based on pooled analysis of six phase 2 randomized controlled trials. Psychopharmacology (Berl). 2019, 236:2735-4. 10.1007\/s00213-019-05249-5","journal-title":"Psychopharmacology (Berl)"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1080\/02791072.2019.1580805","article-title":"Perceived benefits of MDMA-assisted psychotherapy beyond symptom reduction: qualitative follow-up study of a clinical trial for individuals with treatment-resistant PTSD","volume":"51","author":"Barone W","year":"2019","unstructured":"Barone W, Beck J, Mitsunaga-Whitten M, Perl P. Perceived benefits of MDMA-assisted psychotherapy beyond symptom reduction: qualitative follow-up study of a clinical trial for individuals with treatment-resistant PTSD. J Psychoactive Drugs. 2019, 51:199-208. 10.1080\/02791072.2019.1580805","journal-title":"J Psychoactive Drugs"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2019.00650","article-title":"Breakthrough for trauma treatment: safety and efficacy of MDMA-assisted psychotherapy compared to paroxetine and sertraline","volume":"10","author":"Feduccia AA","year":"2019","unstructured":"Feduccia AA, Jerome L, Yazar-Klosinski B, Emerson A, Mithoefer MC, Doblin R. Breakthrough for trauma treatment: safety and efficacy of MDMA-assisted psychotherapy compared to paroxetine and sertraline. Front Psychiatry. 2019, 10:650. 10.3389\/fpsyt.2019.00650","journal-title":"Front Psychiatry"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1038\/s41386-019-0402-z","article-title":"Effects of MDMA on attention to positive social cues and pleasantness of affective touch","volume":"44","author":"Bershad AK","year":"2019","unstructured":"Bershad AK, Mayo LM, Van Hedger K, McGlone F, Walker SC, de Wit H. Effects of MDMA on attention to positive social cues and pleasantness of affective touch. Neuropsychopharmacology. 2019, 44:1698-705. 10.1038\/s41386-019-0402-z","journal-title":"Neuropsychopharmacology"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1097\/NMD.0000000000000499","article-title":"Effects of 3,4-methylenedioxymethamphetamine on patient utterances in a psychotherapeutic setting","volume":"204","author":"Corey VR","year":"2016","unstructured":"Corey VR, Pisano VD, Halpern JH. Effects of 3,4-methylenedioxymethamphetamine on patient utterances in a psychotherapeutic setting. J Nerv Ment Dis. 2016, 204:519-23. 10.1097\/NMD.0000000000000499","journal-title":"J Nerv Ment Dis"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1016\/j.ynstr.2020.100264","article-title":"Transcutaneous cervical vagal nerve stimulation reduces sympathetic responses to stress in posttraumatic stress disorder: a double-blind, randomized, sham controlled trial","volume":"13","author":"Gurel NZ","year":"2020","unstructured":"Gurel NZ, Wittbrodt MT, Jung H, et al.. Transcutaneous cervical vagal nerve stimulation reduces sympathetic responses to stress in posttraumatic stress disorder: a double-blind, randomized, sham controlled trial. Neurobiol Stress. 2020, 13:100264. 10.1016\/j.ynstr.2020.100264","journal-title":"Neurobiol Stress"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbih.2020.100138","article-title":"Transcutaneous vagal nerve stimulation blocks stress-induced activation of Interleukin-6 and interferon-\u03b3 in posttraumatic stress disorder: a double-blind, randomized, sham-controlled trial","volume":"9","author":"Bremner JD","year":"2020","unstructured":"Bremner JD, Gurel NZ, Jiao Y, et al.. Transcutaneous vagal nerve stimulation blocks stress-induced activation of Interleukin-6 and interferon-\u03b3 in posttraumatic stress disorder: a double-blind, randomized, sham-controlled trial. Brain Behav Immun. 2020, 9:2666-3546. 10.1016\/j.bbih.2020.100138","journal-title":"Brain Behav Immun"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1002\/da.22511","article-title":"Psychotherapy versus pharmacotherapy for posttraumatic stress disorder: systemic review and meta-analyses to determine first-line treatments","volume":"33","author":"Lee DJ","year":"2016","unstructured":"Lee DJ, Schnitzlein CW, Wolf JP, Vythilingam M, Rasmusson AM, Hoge CW. Psychotherapy versus pharmacotherapy for posttraumatic stress disorder: systemic review and meta-analyses to determine first-line treatments. Depress Anxiety. 2016, 33:792-806. 10.1002\/da.22511","journal-title":"Depress Anxiety"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2017.00124","article-title":"Non-invasive vagal nerve stimulation effects on hyperarousal and autonomic state in patients with posttraumatic stress disorder and history of mild traumatic brain injury: preliminary evidence","volume":"4","author":"Lamb DG","year":"2017","unstructured":"Lamb DG, Porges EC, Lewis GF, Williamson JB. Non-invasive vagal nerve stimulation effects on hyperarousal and autonomic state in patients with posttraumatic stress disorder and history of mild traumatic brain injury: preliminary evidence. Front Med (Lausanne). 2017, 4:124. 10.3389\/fmed.2017.00124","journal-title":"Front Med (Lausanne)"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.158.8.1227","article-title":"CSF norepinephrine concentrations in posttraumatic stress disorder","volume":"158","author":"Geracioti TD Jr","year":"2001","unstructured":"Geracioti TD Jr, Baker DG, Ekhator NN, et al.. CSF norepinephrine concentrations in posttraumatic stress disorder. Am J Psychiatry. 2001, 158:1227-30. 10.1176\/appi.ajp.158.8.1227","journal-title":"Am J Psychiatry"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1038\/tp.2015.138","article-title":"3,4-methylenedioxymethamphetamine facilitates fear extinction learning","volume":"5","author":"Young MB","year":"2015","unstructured":"Young MB, Andero R, Ressler KJ, Howell LL. 3,4-methylenedioxymethamphetamine facilitates fear extinction learning. Transl Psychiatry. 2015, 5:e634. 10.1038\/tp.2015.138","journal-title":"Transl Psychiatry"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2012.05.023","article-title":"Attention-related Pearce-Kaye-Hall signals in basolateral amygdala require the midbrain dopaminergic system","volume":"72","author":"Esber GR","year":"2012","unstructured":"Esber GR, Roesch MR, Bali S, et al.. Attention-related Pearce-Kaye-Hall signals in basolateral amygdala require the midbrain dopaminergic system. Biol Psychiatry. 2012, 72:1012-9. 10.1016\/j.biopsych.2012.05.023","journal-title":"Biol Psychiatry"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1038\/nn2032","article-title":"Focal brain damage protects against post-traumatic stress disorder in combat veterans","volume":"11","author":"Koenigs M","year":"2008","unstructured":"Koenigs M, Huey ED, Raymont V, Cheon B, Solomon J, Wassermann EM, Grafman J. Focal brain damage protects against post-traumatic stress disorder in combat veterans. Nat Neurosci. 2008, 11:232-7. 10.1038\/nn2032","journal-title":"Nat Neurosci"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2013.12.015","article-title":"The effects of acutely administered 3,4-methylenedioxymethamphetamine on spontaneous brain function in healthy volunteers measured with arterial spin labeling and blood oxygen level-dependent resting state functional connectivity","volume":"78","author":"Carhart-Harris RL","year":"2015","unstructured":"Carhart-Harris RL, Murphy K, Leech R, et al.. The effects of acutely administered 3,4-methylenedioxymethamphetamine on spontaneous brain function in healthy volunteers measured with arterial spin labeling and blood oxygen level-dependent resting state functional connectivity. Biol Psychiatry. 2015, 78:554-62. 10.1016\/j.biopsych.2013.12.015","journal-title":"Biol Psychiatry"},{"key":"ref44","doi-asserted-by":"crossref","DOI":"10.1038\/sj.npp.1395197","article-title":"Psychological and cardiovascular effects and short-term sequelae of MDMA (\"ecstasy\") in MDMA-na\u00efve healthy volunteers","volume":"19","author":"Vollenweider FX","year":"1998","unstructured":"Vollenweider FX, Gamma A, Liechti M, Huber T. Psychological and cardiovascular effects and short-term sequelae of MDMA (\"ecstasy\") in MDMA-na\u00efve healthy volunteers. Neuropsychopharmacology. 1998, 19:241-51.","journal-title":"Neuropsychopharmacology"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/58217-the-efficacy-of-mdma-34-methylenedioxymethamphetamine-for-post-traumatic-stress-disorder-in-humans-a-systematic-review-and-meta-analysis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:28:29Z","timestamp":1707506909000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/58217-the-efficacy-of-mdma-34-methylenedioxymethamphetamine-for-post-traumatic-stress-disorder-in-humans-a-systematic-review-and-meta-analysis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,17]]},"references-count":44,"URL":"https:\/\/doi.org\/10.7759\/cureus.15070","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5,17]]}}}